

REPLY UNDER 37 CFR 1.116-EXPEDITED PROCEDURE-  
TECHNOLOGY CENTER 1654Law Offices of  
SENNIGER POWERSOne Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102Telephone (314) 231-5400  
Facsimile (314) 231-4342RECEIVED  
CENTRAL FAX CENTER

JUL 03 2006

## FACSIMILE TRANSMITTAL COVER SHEET

DATE: 07/03/06 FILE NUMBER: DI-5954 (BXTR 9004.6)  
PTO FACSIMILE NUMBER: 571-273-8300PLEASE DELIVER THIS FACSIMILE TO: MAIL STOP AFTER FINAL  
THIS FACSIMILE IS BEING SENT BY: Kathleen M. Petrillo  
NUMBER OF PAGES: 38 INCLUDING COVER SHEETTIME SENT: 1:40 pm OPERATOR'S NAME Kathleen M. Petrillo

## CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to  
the Patent and Trademark Office on the date shown below.

Kathleen M. Petrillo

Typed or printed name of person signing certification

Signature

Date

Type of paper transmitted: Response to Final Office ActionApplicant's Name: Fabian Somers et al.Serial No.: 10/683,549 Examiner: J. RusselFiling Date: 10/10/03 Art Unit: 1654 Confirmation No.: 2624Application Title: STABILIZATION OF PHARMACEUTICAL PROTEIN  
FORMULATIONS WITH SMALL PEPTIDESIF YOU DO NOT RECEIVE ALL PAGES CLEARLY, CALL BACK AS SOON AS  
POSSIBLE. CONFIRMING NUMBER IS (314) 231-5400.

DI-5954 (BXTR 9004.6)  
PATENT

**REPLY UNDER 37 CFR 1.116-EXPEDITED PROCEDURE-  
TECHNOLOGY CENTER 1654**

**RECEIVED**  
**CENTRAL FAX CENTER**  
**JUL 03 2006**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Somers et al.

Art Unit 1654

Serial No. 10/683,549

Filed October 10, 2003

Confirmation No. 2624

For **STABILIZATION OF PHARMACEUTICAL PROTEIN FORMULATIONS  
WITH SMALL PEPTIDES**

Examiner Jeffrey E. Russel

July 3, 2006

**AMENDMENT RESPONDING TO FINAL OFFICE ACTION**  
**DATED JANUARY 6, 2006**

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,  
SIR:

In response to the Final Office action dated January 6, 2006 and the Advisory actions dated March 28, 2006 and June 13, 2006, please consider the following remarks.

**Amendments to the Claims begin on page 2 of this paper.**

**Remarks begin on page 5 of this paper.**

**Conclusion is on page 15 of this paper.**